Skip to content

Abstract 5578: Adverse Clinical Events in Secondary Stroke Prevention: A Nationwide Cohort Study in Sweden

Nov 2026 · Circulation · 0 citations

Abstract

Introduction: Despite improvements in the management of ischemic stroke (IS), survivors continue to face high risk of recurrent events, including IS, major adverse vascular events (MAVE), and bleeding. Long-term real-world evidence is needed to characterize the burden of recurrent events under current secondary stroke prevention (SSP) practice. Research question: What is the occurrence of adverse clinical events in routine practice in Sweden following non-cardioembolic IS in adults receiving guideline-directed SSP therapy? Methods: Using a cohort study design, nationwide linked registers were used to identify adults with incident IS diagnosed in inpatient or specialist outpatient care (2013 to 2023). The index was the date of discharge recorded in Riksstroke. Exclusion criteria were prior IS and atrial fibrillation (12 years prior to index), immigration (5 years), active cancer and anticoagulant use (1 year), and death during index hospitalization. Baseline characteristics were assessed for the preceding 12-month period. Incidence rates (IR) of clinical events per 1000 person-years (PY) were estimated for years 1-3; cumulative incidence functions (CIF) accounted for death (or non-cardiovascular death for major adverse cardiac events [MACE]) as a competing risk. Registered ICD-10 codes were used to ascertain the first recorded occurrence of each event after index. Stratified analyses included age group at index and antiplatelet therapy (APT) regimen prescribed and dispensed within 7 days after discharge. Patients were followed up to a maximum of 12 years (earliest of event, death, emigration, or 31 December 2024). Results: 57,172 patients were included in the analyses (index: mean age 70 years; 47% female; 94% alert per Reaction Level Scale 1985). At year 1, IR for all-cause mortality (ACM) was 71.0 events per 1000 PYs, of which CV mortality was 39.1 (Table 1). The most frequent individual events were minor bleeding (39.7), IS (37.8), and major bleeding (34.0). For MAVE and MACE, IRs were 84.7 and 80.2, respectively. At year 1, IRs were higher across all events than at years 2 and 3. Stratified analyses showed that CIF of ACM was highest in older and lowest in younger patients, which was also observed for IS from year 6 onwards (Figure 1). When stratified by treatment regimen, no APT and single APT (SAPT) were associated with higher CIF of ACM compared to dual APT (DAPT). CIF of IS was comparable between SAPT and DAPT, and higher in patients with no APT (Figure 2). The latter associations were more apparent within years 3 and 4 post index. Conclusions: This analysis shows that IS survivors in Sweden continue to face substantial long-term clinical burden from mortality and IS, with the highest IRs observed in the first year post IS. The persistent residual burden under contemporary SSP guidelines warrants further investigation into strategies to reduce future events.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.